The trial accomplished the two its Most important endpoints, with semaglutide two.4 mg demonstrating statistically important and exceptional advancements in liver fibrosis without any worsening of steatohepatitis, and also resolution of steatohepatitis without any worsening of liver fibrosis in those with MASH in comparison with placebo.1Mounjaro c… Read More